Printer Friendly

Alligator Bioscience announces presentation of ADC-1013 intratumoural clinical phase I study results at SITC in November 2017.

M2 PHARMA-September 22, 2017-Alligator Bioscience announces presentation of ADC-1013 intratumoural clinical phase I study results at SITC in November 2017


Alligator Bioscience (STO: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumour-directed immunotherapy, announced on Thursday the presentation of results from a clinical phase I study of the drug candidate ADC-1013 (JNJ-64457107) at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, held from 8 November 2017 to 12 November 2017, in National Harbour, Maryland, US.

According to Alligator Bioscience, it will give both an oral and poster presentation at the SITC conference with the title, 'First-in-human study with intratumoral administration of a CD40 agonistic antibody: preliminary results with ADC -1013/JNJ-64457107 in advanced solid malignancies'.

ADC-1013 is a drug candidate intended for immunotherapy of different types of cancer. In August 2015, Alligator had licensed global development rights for ADC-1013 to Janssen Biotech Inc. In October 2016, Janssen Biotech had started a second phase I clinical study, which is an intravenous dose escalation study with ADC-1013 (JNJ-64457107).

The ADC-1013 clinical Phase I study to be presented is a multicentre, open-label phase I study in patients with advanced solid tumours evaluating safety and tolerability, pharmacokinetics, immunogenicity, biomarker response and clinical response. The study is a dose -escalation study involving intratumoural and intravenous administration of ADC -1013 at five hospitals in Sweden, Denmark and the UK. The study was performed by Alligator and includes 24 patients and ten different tumour types.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 22, 2017
Previous Article:PTC Therapeutics awards stock options to 13 new employees under Nasdaq Listing Rule 5635(c)(4).
Next Article:Synthego adds new member to advisory board.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters